Radioligand Therapy in the Clinic

Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann

Lutetium-177 PSMA Radioligand Therapy Advances to Earlier mCRPC Setting - Daniel Petrylak & Steven Finkelstein

First Patient Experience with Pre-Chemotherapy Pluvicto™ for mCRPC Treatment - James Wasielewski

First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein

Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center - Thomas Hope

Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore

Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo

Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor

Methods for Preparation and Administration of Pluvicto™ (177Lu-PSMA-617) - Kendra Harris

Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris

Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo

Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris

Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris

Building a Sustainable Radioligand Treatment Clinic – Charlotte Manogue

Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate Cancer in the Clinic – Charlotte Manogue and Oliver Sartor

Establishing A Theranostics Clinic for Advanced Prostate Cancer – Kendra Harris and Charlotte Manogue

The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris